Vimta Labs Ltd (VIMTALABS)

Healthcare · Healthcare · NSE · Updated 1 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹644.35 ↓ 3.27% (1Y)

🎯 Key Takeaways

Vimta Labs is in a strategic investment phase, transitioning from stable profitability to growth-oriented expansion with a focus on high-margin pharma services and biologics. The company is leveraging strong export demand and customer retention to drive 13.
Revenue grew 6.1% QoQ to ₹90 in Q3FY25.
⚠️ 1) Overreliance on export markets, particularly the U.S., exposes the company to geopolitical and regulatory headwinds despite current stability. 2) M

Market Cap

₹2,878

P/E Ratio

23.3

P/B Ratio

9.00

ROE

19.2%

ROCE

24.3%

Debt/Equity

0.06

Div Yield

0.31%

Promoter

35.7%

✨ Ask AI About VIMTALABS 📊 Interactive Charts

📖 The Story

Vimta Labs is in a strategic investment phase, transitioning from stable profitability to growth-oriented expansion with a focus on high-margin pharma services and biologics. The company is leveraging strong export demand and customer retention to drive 13.7% YoY revenue growth while reinvesting in capacity expansion to capture long-term structural tailwinds in healthcare outsourcing.

📰 What's Happening

In Q1 FY27, Vimta Labs reported 13.7% YoY revenue growth to INR1,129 crores, driven by pharma services and clinical research recovery, with export revenue contributing ~40% and strong U.S. traction. Management highlighted 60% capacity utilization of its 200,000 sq. ft. infrastructure and 90% customer retention, supporting cross-selling opportunities from biologics integration. Capex of INR80 crores is planned for FY27, including INR10 crores for Biologics CRADS and INR100 crores for a new Hyderabad lab expansion. Despite margin compression (PAT margin declined to 18.6% from 18.9%), profitability remains stable with PAT up 11.4% YoY to INR210 crores. Management expects operating margins to remain stable despite near-term softness in food testing, offset by growth in core segments.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Revenue	80	75	85	90
Operating Profit	16	18	22	23
OPM %	20.5%	24.0%	25.5%	25.9%
Net Profit	12	12	15	22
EPS	₹5.58	₹5.54	₹6.88	₹9.65

Revenue has grown sequentially from ₹75 crores in Jun 2024 to ₹85 crores in Sep 2024 and ₹90 crores in Dec 2024, with PAT margin holding firm at ~18-20% despite modest base expansion. This growth trajectory aligns with management’s disclosed focus on scaling pharma services and biologics, supported by 13.7% YoY revenue growth in Q1 FY27. The slight margin compression (OPM down to 25.9% from 25.5% in prior quarters) reflects operational scaling, but EBITDA growth outpacing revenue suggests improving operational leverage. The company is reinvesting profits into capacity to sustain 20-25% growth targets, indicating a deliberate shift from consolidation to expansion.

🔮 Management Outlook & What's Next

Management has not provided specific forward financial guidance but emphasized ambitions to sustain 20-25% growth through capacity expansion and biologics integration. Key upcoming investments include INR100 crores for a Hyderabad lab expansion, INR35 crores for Biologics, and INR40-45 crores for Electronics/Electrical testing. Management highlighted cross-selling potential from biologics and strong customer retention as tailwinds, while planning to offset softness in food testing through domestic market focus. The absence of formal guidance suggests confidence in organic growth execution rather than major strategic shifts.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2023	Mar 2024	Mar 2024	Mar 2025
Equity Capital	4	4	4	4
Reserves	277	292	315	338
Borrowings	15	19	19	12
Total Liabilities	362	377	400	440
Fixed Assets	157	164	171	170
Investments	0	0	0	0
Total Assets	362	377	400	440

The balance sheet shows a strong capital-light profile with minimal borrowings (₹12 crores as of Mar 2025) and equity of just ₹4 crores, reflecting a lean capital structure. Reserves have grown steadily from ₹292 crores to ₹338 crores over two years, indicating retained earnings are being used to fund growth without significant debt accumulation. This supports a conservative capital allocation strategy focused on reinvestment rather than leverage, consistent with management’s Capex plans being funded through internal cash flows and selective financing.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2024
Operating	+61
Investing	-76
Financing	-2
Net Cash Flow	-17

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	36.0%	35.9%	35.9%	35.7%
FII	4.3%	4.6%	4.9%	4.4%
DII	0.9%	0.1%	0.1%	0.4%
Public	24.6%	25.1%	25.0%	25.0%
# Shareholders	55,933	54,467	51,623	50,190

Institutional investor interest has recently increased, with FII holdings rising from 4.33% in Q2FY26 to 4.89% in Q4FY26, while DII holdings remain low but stable. Promoter holding remains steady at ~35.67%, with no signs of dilution or selling pressure. The growing number of public shareholders (50,190 in Q1FY27) and sustained institutional accumulation suggest improving market confidence, though foreign ownership remains modest. No promoter pledging or significant changes in shareholding pattern were disclosed.

⚖️ Peer Comparison — Healthcare

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
APOLLOHOSP	1.27 L Cr	61.0	22.1%	22.9%	0.60
MANIPALHOS	1.00 L Cr	—	—	—	1.25
MAXHEALTH	99,174	68.0	14.4%	13.6%	0.27
FORTIS	68,550	65.4	13.3%	10.8%	0.29
ASTERDM	65,881	122.3	17.2%	11.9%	0.21
MEDANTA	39,854	71.6	21.9%	16.3%	0.10
NH	38,979	47.5	13.7%	18.0%	1.07
LALPATHLAB	32,521	46.8	29.6%	21.8%	0.00
KIMS	31,685	147.9	9.7%	8.7%	1.44
POLYMED	17,871	56.7	15.1%	11.3%	0.06

🔗 Peer Stock Analyses

APOLLOHOSP MANIPALHOS MAXHEALTH FORTIS ASTERDM

⚠️ Risk Factors

1) Overreliance on export markets, particularly the U.S., exposes the company to geopolitical and regulatory headwinds despite current stability. 2) Margin pressure in food testing segments, which management acknowledges as a near-term softness area, could impact overall profitability if not offset by stronger performance in pharma and biologics. 3) Execution risk in large-scale Capex projects, including the Hyderabad lab and Biologics CRADS, which require precise timing and cost control to deliver anticipated returns.

📋 Recent Filings

🧠 Analyst's Read

Vimta Labs is executing a disciplined growth strategy with improving operational leverage and stable profitability, supported by strong export demand and customer retention. Investors should monitor execution of Capex plans and the pace of recovery in food testing, as near-term margin stability hinges on balancing softness in certain segments against growth in high-margin pharma and biologics services.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on VIMTALABS

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when VIMTALABS files new disclosures

Track VIMTALABS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track VIMTALABS — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd